Pretty strong statements here, from the company:
Post# of 50
Posted On: 08/17/2014 6:41:46 PM
Pretty strong statements here, from the company:
•The Hepatitis C program continued to make progress. Cocrystal Pharma has selected CDI-244 for development as a treatment for patients with Hepatitis C (HCV). CDI-244, our clinical candidate, has the following key properties: (1) potent activity against all HCV genotypes (pan-genotypic activity), (2) highly effective against HCV drug resistant variants, and (3) a favorable pharmacokinetic profile. Cocrystal Pharma plans regulatory filings to initiate clinical trials of CDI-244 in early 2015.
•Cocrystal scientists have made excellent progress, discovering potent inhibitors of the influenza endonuclease, an enzyme which is essential for viral genome replication. The mechanism of action of these inhibitors is different from that of approved neuraminidase inhibitors such as Tamiflu. Cocrystal's endonuclease inhibitors are expected to show a higher barrier to resistance. Selection of a lead compound for clinical development is planned to occur by early 2015. Regulatory filings to initiate clinical studies for influenza are planned for December 2015.
CEO Dr. Gary Wilcox stated, "We are pleased to report that we continue to move our drug candidates closer towards clinical development. By employing unique technologies and Nobel Prize winning expertise to drug discovery, we believe we have established a technology pipeline designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. We look forward to sharing future milestones with our stakeholders as they develop."
•The Hepatitis C program continued to make progress. Cocrystal Pharma has selected CDI-244 for development as a treatment for patients with Hepatitis C (HCV). CDI-244, our clinical candidate, has the following key properties: (1) potent activity against all HCV genotypes (pan-genotypic activity), (2) highly effective against HCV drug resistant variants, and (3) a favorable pharmacokinetic profile. Cocrystal Pharma plans regulatory filings to initiate clinical trials of CDI-244 in early 2015.
•Cocrystal scientists have made excellent progress, discovering potent inhibitors of the influenza endonuclease, an enzyme which is essential for viral genome replication. The mechanism of action of these inhibitors is different from that of approved neuraminidase inhibitors such as Tamiflu. Cocrystal's endonuclease inhibitors are expected to show a higher barrier to resistance. Selection of a lead compound for clinical development is planned to occur by early 2015. Regulatory filings to initiate clinical studies for influenza are planned for December 2015.
CEO Dr. Gary Wilcox stated, "We are pleased to report that we continue to move our drug candidates closer towards clinical development. By employing unique technologies and Nobel Prize winning expertise to drug discovery, we believe we have established a technology pipeline designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. We look forward to sharing future milestones with our stakeholders as they develop."
(0)
(0)